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SUMMARY		
	
Background:	 Epidemiological	 studies	 have	 linked	 lifestyle,	 cardiometabolic,	
reproductive,	developmental	and	inflammatory	factors	with	colorectal	cancer	(CRC)	
risk.	However,	 it	 is	unclear	which	specific	 factors	 influence	risk	and	the	strength	of	
effects.		
	
Methods:	Under	a	random-effects	model	we	examined	the	relationship	between	39	
potentially	 modifiable	 risk	 factors	 and	 CRC	 using	 genetic	 variants	 as	 instruments	
using	 two-sample	 Mendelian	 randomisation	 (MR),	 thereby	 limiting	 bias	 from	
confounding	and	reverse	causation.	Using	genetic	data	on	26,397	CRC	patients	and	
41,481	 controls,	 we	 calculated	 odds	 ratios	 of	 CRC	 risk	 per	 genetically	 predicted	
standard	deviation	unit	increase	in	each	putative	risk	factor	(ORSD).	Evidence	of	MR	
assumption	violation	was	sought	using	MR-Egger	regression.	A	Bonferroni-corrected	
threshold	of	P=1.3x10-3	was	considered	significant,	and	P<0.05	considered	suggestive	
of	an	association.	
	
Findings:	No	 putative	 risk	 factors	were	 significantly	 associated	with	 CRC	 risk	 after	
correction	for	multiple	testing.	Suggestive	associations	were	however	seen	between	
genetically	 predicted	 body	 fat	 percentage	 (ORSD=1.14,	 95%	 confidence	 interval	
[CI]=1.03-1.25,	 P=0.0086),	 BMI	 (ORSD=1.09,	 95%	 CI=1.01-1.17,	 P=0.023),	 waist	
circumference	 (ORSD=1.13,	 95%	 CI=1.02-1.26,	 P=0.018)	 and	 basal	 metabolic	 rate	
(ORSD=1.10,	 95%	 CI=1.03-1.18,	 P=0.0079)	 with	 higher	 CRC	 risk.	 Low-density	
lipoprotein	cholesterol	level	(ORSD=1.14,	95%	CI=1.04-1.25,	P=0.0056)	and	circulating	
serum	 iron	 (ORSD=1.17,	 95%	 CI=1.00-1.36,	 P=0.049)	 also	 showed	 suggestive	
associations	with	increased	CRC	risk.	A	suggestive	association	was	observed	between	
serum	vitamin	B12	concentration	and	 increased	CRC	risk	 (ORSD=1.21,	95%	CI=1.04–
1.42,	 P=0.016),	 although	 potential	 pleiotropy	 amongst	 genetic	 variants	 used	 as	
instruments	for	this	factor	constrains	the	finding.	Low	blood	selenium	concentration	
also	 showed	 suggestive	 association	 with	 CRC	 (ORSD=0.85,	 95%	 CI=0.75-0.96,	
P=0.0078),	 albeit	 based	 on	 a	 single	 variant.	 CRC	 risk	 was	 not	 associated	with	 any	
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reproductive	 factor,	 serum	 calcium	 or	 circulating	 25-hydroxyvitamin	 D	
concentrations.		
	
Interpretation:	 This	 analysis	 highlights	 a	 number	 of	modifiable	 targets	 for	 primary	
prevention	 of	 CRC,	 including	 lifestyle,	 obesity	 and	 cardiometabolic	 factors	 that	
should	inform	public	health	policy.		 	
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RESEARCH	IN	CONTEXT	
	
Evidence	 before	 this	 study:	 We	 searched	 PubMed	 to	 identify	 dietary,	 lifestyle,	
obesity-related,	 inflammatory,	 reproductive	 and	 developmental	 factors	 that	 had	
been	 assessed	 in	 observational	 epidemiological	 studies	 potentially	 influencing	
colorectal	 cancer	 (CRC)	 risk.	 Studies	 provide	 strong	 evidence	 for	 body	mass	 index	
(BMI)	and	hypercholesterolaemia	being	associated	with	increased	CRC	risk.	For	most	
other	factors	there	is	inconclusive	evidence	from	conventional	observational	studies	
to	reliably	establish	specific	associations.	
	
Added	 value	 of	 this	 study:	 Mendelian	 randomisation	 exploits	 germline	 genetic	
variants	 as	 instrumental	 variables	 for	 putative	 risk	 factors.	 Because	 these	 genetic	
variants	 are	 randomly	 assorted	 at	 conception	 they	 are	 not	 influenced	 by	 reverse	
causation	 and	 so	 can	 provide	 evidence	 for	 causal	 relationships.	 We	 used	 genetic	
variants	 for	 39	 potentially	modifiable	 CRC	 risk	 factors	 in	 26,397	 CRC	 patients	 and	
41,481	 controls.	 There	was	 suggestive	 evidence	 for	 associations	 of	 serum	 vitamin	
B12,	iron	and	selenium	concentrations	with	CRC.	In	addition	to	providing	suggestive	
evidence	 for	a	 causal	 relationship	between	higher	BMI	and	 increased	CRC	 risk,	we	
found	 evidence	 for	 an	 association	 between	 genetically	 predicted	 low-density	
lipoprotein	with	 risk	 of	 CRC.	No	 associations	with	CRC	 risk	were	 identified	 for	 any	
reproductive	factor.	
	
Implications	 of	 all	 the	 available	 evidence:	 These	 data	 provide	 two	main	 findings:	
Firstly,	 genetic	 corroboration	 of	 causal	 relationships	 between	 higher	 BMI	 and	
hypercholesterolaemia	 and	 elevated	 CRC	 risk.	 Secondly,	 findings	 support	 the	
assertion	that	vitamin	B12	supplementation	should	be	 limited	to	 individuals	with	a	
known	 indication,	 such	 as	 proven	 deficiency.	 Our	 analysis	 highlights	 important	
targets	 for	 primary	 prevention	 of	 CRC,	 including	 lifestyle,	 obesity	 and	
cardiometabolic	factors.	
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INTRODUCTION	
	
Colorectal	 cancer	 (CRC)	 is	 the	 third	most	 common	 diagnosed	malignancy	 and	 the	
second	leading	cause	of	cancer-related	death	in	the	world,	accounting	for	around	1.8	
million	 new	 cases	 and	 860,000	 deaths	 in	 2018(1).	 Based	 on	 current	 demographic	
trajectories,	it	is	projected	that	the	global	burden	of	CRC	will	increase	by	72%	to	over	
3	million	 new	 cases	 and	by	 82%	 to	 1.6	million	 cancer	 deaths	 annually	 by	 2040(1).	
Differences	 in	 CRC	 incidence	 between	 countries	 and	 migration	 studies	 have	
implicated	dietary	and	other	lifestyle	factors	in	CRC	development(2).	In	view	of	this	
there	 is	 increasing	 interest	 in	 developing	 public	 health	 programs	 to	 reduce	 CRC	
incidence	by	targeting	modifiable	risk	factors.	
	
The	 World	 Cancer	 Research	 Fund	 (WCRF)	 and	 The	 American	 Institute	 for	 Cancer	
Research	 (AICR)	 have	 concluded	 that	 there	 is	 convincing	 evidence	 for	 body	 mass	
index	(BMI)	and	alcohol	intake	being	causally	associated	with	increased	CRC	risk,	and	
physical	activity	being	causally	associated	with	reduced	CRC	risk(3).	Furthermore,	 it	
is	 probable	 that	 red	 meat	 intake	 is	 causally	 associated	 with	 increased	 CRC	 risk,	
whereas	 dietary	 fibre,	 dairy	 products	 and	 calcium	 supplements	 are	 causally	
associated	with	a	lower	risk(3).	For	most	other	factors	there	is	inconclusive	evidence	
from	these	conventional	observational	studies	to	reliably	establish	associations(3).	
	
Much	 of	 the	 available	 evidence	 for	 a	 causal	 relationship	 between	 potentially	
modifiable	 factors	and	CRC	risk	 is	derived	 from	observational	 studies(3),	which	are	
susceptible	 to	 confounding	 bias	 and	 reverse	 causation(4).	 Moreover,	 data	 from	
randomised	trials	tend	to	be	scarce	and	often	inconclusive(5,	6).	Finally,	establishing	
which	specific	 components	of	 risk	 factors	 such	as	diet	are	 important	 is	notoriously	
problematic	in	conventional	observational	epidemiological	studies(7).		
	
Mendelian	randomisation	(MR)	is	an	analytical	approach,	whereby	germline	genetic	
variants	 are	used	 as	proxies,	 or	 instrumental	 variables,	 for	 putative	 risk	 factors(8).	
Because	 these	 genetic	 variants	 are	 randomly	 assorted	 at	 conception	 they	 are	 not	
influenced	 by	 reverse	 causation,	 and	 in	 the	 absence	 of	 pleiotropy	 (i.e.	 genetic	
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variants	 being	 associated	with	 the	disease	 through	 alternative	pathways)	 they	 can	
provide	 unconfounded	 estimates	 of	 disease	 risk(8).	 Since	 MR-based	 studies	 can	
circumvent	many	limitations	of	conventional	observational	studies	the	methodology	
is	 increasingly	 being	 employed	 as	 an	 effective	 strategy	 to	 examine	 the	 potential	
impact	of	interventions	on	disease	risk.		
	
We	have	investigated	potentially	causal	and	modifiable	CRC	risk	factors	using	a	two-
sample	 MR	 framework	 (Supplementary	 Figure	 1)	 whereby	 genetic	 variants	
associated	with	 relevant	 risk	 factors	 as	 instrumental	 variables	were	 first	 identified	
from	genome-wide	association	studies	 (GWAS).	We	then	evaluated	 the	association	
of	these	instrumental	variables	with	CRC	in	a	large	GWAS	comprising	26,397	cases	of	
CRC	and	41,481	control	subjects(9).	
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METHODS	
	
Identification	of	potentially	modifiable	risk	factors	
As	well	 as	 evaluating	 dietary,	 lifestyle,	 obesity-related,	 inflammatory,	 reproductive	
and	developmental	factors	that	had	been	the	subject	of	the	report	by	the	WCRF	and	
AICR(3),	we	also	searched	PubMed	to	identify	additional	modifiable	CRC	risk	factors	
that	have	been	reviewed	in	published	epidemiological	meta-analyses	or	MR	analyses	
(Supplementary	Table	1;	Supplementary	Information).		
	
Genetic	instruments	for	putative	risk	factors		
Single	 nucleotide	 polymorphisms	 (SNPs)	 associated	 with	 putative	 risk	 factor	 traits	
suitable	 for	 use	 in	 MR	 analysis	 were	 identified	 from	 the	 largest	 GWAS	 or	 meta-
analysis	 of	 each	 trait	 conducted	 to	 date	 (Table	 1;	 Supplementary	 Table	 2;	
Supplementary	 Information).	 Traits	 were	 only	 considered	 if	 the	 proportion	 of	
variance	 explained	 (PVE)	 by	 the	 associated	 SNPs	 was	 >0.1%.	 PVE	 estimates	 were	
either	 obtained	 from	 the	 publication	 or	 computed	 directly	 from	 the	 association	
statistics	(Table	1)(10).	Suitable	genetic	instruments	were	not	available	for	many	risk	
factors,	 such	 as	physical	 activity,	 dietary	patterns	 and	 vitamin	C	 intake,	 precluding	
their	 inclusion	 in	 this	 study	 (Supplementary	 Table	 1).	 We	 considered	 only	
continuous	 traits,	 as	 analysis	 of	 binary	 traits	 (such	 as	 disease	 status)	 with	 binary	
outcomes	 in	 two-sample	 MR	 frameworks	 can	 result	 in	 inaccurate	 causal	
estimates(11).	 Only	 SNPs	 associated	 with	 each	 trait	 at	 P<5×10−8	 in	 GWAS	 of	
European	 populations	 with	 a	 minor	 allele	 frequency	 >0.01	 were	 considered	 as	
potential	instruments.	To	mitigate	against	co-linearity	between	SNPs,	which	can	bias	
causal	 effect	 estimates,	we	 used	MR-Base	 to	 exclude	 correlated	 SNPs	 at	 a	 linkage	
disequilibrium	threshold	of	r2>0.01,	retaining	those	SNPs	with	the	strongest	effect	on	
the	associated	trait(12).		
	
Colorectal	cancer	genotyping	data		
To	 examine	 the	 association	 of	 each	 genetic	 instrument	 with	 CRC	 risk,	 we	 used	
summary	 CRC	 effect	 estimates	 and	 corresponding	 standard	 errors	 (SEs)	 from	 a	
recent	 meta-analysis	 of	 15	 CRC	 GWAS(9).	 After	 imputation,	 this	 meta-analysis	
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related	>10	million	genetic	variants	 to	CRC	 in	 individuals	of	European	ancestry.	UK	
BioBank	data	were	used	 to	obtain	 genetic	 instruments	 for	 age	 at	menarche,	 basal	
metabolic	 rate,	birth	weight,	body	 fat	percentage	and	waist	circumference,	as	well	
as	in	one	of	the	CRC	GWAS	meta-analysed	by	Law	et	al.(9).	To	avoid	sample	overlap	
biasing	this	two-sample	MR	analysis(13)	we	therefore	excluded	the	UK	BioBank	CRC	
GWAS	 and	 recomputed	 association	 statistics	 using	 the	 remaining	 14	 CRC	 GWAS	
(Supplementary	 Table	 3)	 with	 an	 inverse	 variance	 weighted	 (IVW)	 fixed-effects	
model,	as	described	by	Law	et	al.(9).		After	exclusion	of	the	UK	BioBank	CRC	GWAS,	
the	meta-analysis	 comprised	 26,397	 patients	 and	 41,481	 controls.	 SNPs	with	 poor	
imputation	quality	(i.e.	 info	score	<0.8)	were	not	considered	 in	the	MR	analysis.	As	
some	potentially	modifiable	reproductive	risk	factors	are	female-specific,	where	sex	
data	were	available	we	further	computed	CRC	association	statistics	using	only	7,952	
female	cases	and	11,680	 female	controls.	We	used	MR-Base	to	harmonize	SNPs	to	
ensure	 that	 the	 effect	 estimates	 of	 each	 SNP	 on	 each	 trait	 and	 CRC	 risk	
corresponded	 to	 the	 same	 allele(12).	 Effect	 estimates	 for	 the	 association	 of	 each	
trait	SNP	with	CRC	risk	are	shown	in	Supplementary	Table	2.	For	vitamins,	positive	
beta	 values	 indicate	 that	 the	 effect	 allele	 is	 associated	 with	 increased	 serum	
concentration.	
	
Statistical	analysis	
The	MR	methodology	is	predicated	on	the	assumption	that	genetic	variants	used	as	
instruments	 for	 a	 risk	 factor	 are	 associated	 with	 the	 risk	 factor	 and	 not	 with	 a	
confounder	 or	 alternative	 causal	 pathway	 (Figure	 1).	 Additionally,	 to	 accurately	
estimate	the	size	of	the	causal	effect,	the	associations	depicted	in	Figure	1	must	be	
linear	and	unaffected	by	statistical	interactions(14).	We	estimated	causal	effects	for	
each	 SNP	 using	 the	Wald	 ratio	 (Supplementary	 Figure	 2).	 For	 traits	with	multiple	
SNPs	 available	 as	 instruments,	 causal	 effects	 were	 estimated	 using	 the	 random-
effects	 maximum	 likelihood	 estimation	 (MLE-RE)	 method(15).	 To	 assess	 the	
robustness	of	our	findings,	we	also	obtained	weighted	median	estimates	(WME)(16)	
and	mode-based	estimates	 (MBE)(17).	We	used	the	MR-Egger	regression	approach	
to	 evaluate	 the	 extent	 to	 which	 directional	 pleiotropy	 may	 affect	 the	 causal	
estimates(18).	Finally,	we	conducted	leave-one-out	analysis	using	the	multiplicative	
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random-effects	 inverse	 variance	 weighted	 method(12)	 to	 examine	 the	 impact	 of	
outlying	 and	 pleiotropic	 SNPs	 on	 causal	 estimates	 (Supplementary	 Table	 4).	 I2	
statistics	were	computed	to	estimate	the	proportion	of	variance	across	SNPs	due	to	
heterogeneity	 (Figure	 2;	 Supplementary	 Table	 5).	 Results	 are	 reported	 as	 odds	
ratios	 (ORSD)	 and	95%	confidence	 intervals	 (CIs)	 per	 genetically	predicted	 standard	
deviation	 (SD)	 unit	 increase	 in	 each	 putative	 risk	 factor.	 To	 address	 the	 issue	 of	
multiple	testing,	we	applied	a	Bonferroni-corrected	significance	threshold	computed	
as	 0.0013	 (i.e.	 0.05/39	 putative	 risk	 factors).	 0.0013<P<0.05	 was	 considered	 as	
suggestive	 of	 a	 potential	 association.	 The	 power	 of	 MR	 to	 demonstrate	 a	 causal	
effect	 depends	 on	 the	 proportion	 of	 variance	 in	 the	 risk	 factor	 explained	 by	 the	
genetic	variants	used	as	instruments,	and	we	therefore	estimated	study	power	at	an	
alpha	 of	 0.05	 for	 each	 risk	 factor	 a	 priori	 (Table	 1)(19).	 Statistical	 analyses	 were	
performed	using	R	v3.4.0	and	MR	analyses	were	performed	using	MR-Base(12).	
	
Role	of	the	funding	sources	
Funders	had	no	role	in	study	design,	in	the	collection,	analysis	and	interpretation	of	
data,	or	in	writing	the	report.	The	corresponding	author	had	full	access	to	all	of	the	
data	and	the	final	responsibility	to	submit	for	publication.	 	
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RESULTS	
	
Diet	and	lifestyle	factors	
Under	 a	 MLE-RE	 model,	 a	 suggestive	 association	 was	 seen	 between	 genetically	
predicted	 serum	 vitamin	 B12	 concentration	 and	 higher	 CRC	 risk	 (ORSD=1.21,	 95%	
CI=1.04–1.42,	P=0.016),	however	substantial	heterogeneity	exists	between	the	SNPs	
used	as	IVs	(I2=79.1).	Leave-one-out	analysis	identified	SNP	rs602662	at	a	known	CRC	
risk	locus	as	having	a	strong	influence	on	the	causal	estimate	(Supplementary	Table	
4)(9).	 Expression	 quantitative	 trait	 loci	 analysis	 has	 indicated	 that	 variation	 at	 this	
potentially	pleiotropic	 locus	may	 influence	CRC	 risk	 through	FUT2	and	 interactions	
with	 intestinal	bacteria	and	viruses(9).	There	was	a	suggestive	association	between	
genetically	 predicted	 greater	 serum	 iron	 concentration	 and	 higher	 CRC	 risk	
(ORSD=1.17,	95%	CI=1.00-1.36,	P=0.049),	with	no	outlying	genetic	variant	 identified	
(Supplementary	 Figure	2).	There	was	also	a	suggestive	association	between	higher	
serum	 selenium	 concentration	 and	 lower	 CRC	 risk	 (ORSD=0.85,	 95%	 CI=0.75-0.96,	
P=0.0078)	 albeit	 based	 on	 only	 one	 SNP.	 Genetically	 predicted	 alcohol	 and	 coffee	
consumption,	 and	 blood	 methionine,	 zinc,	 25-hydroxyvitamin	 D,	 carotenoids,	
calcium	and	vitamins	A	 (retinol),	B6	and	E	concentrations,	showed	no	evidence	 for	
association	with	CRC	risk	 (Figure	 2).	Causal	effect	estimates	 for	serum	vitamin	B12	
concentration	was	similar	 in	sensitivity	analyses	using	the	WME	and	MBE	methods	
(Supplementary	 Table	 5).	MR-Egger	 regression	 showed	 no	 evidence	 of	 directional	
pleiotropy	 in	 the	 analyses	 of	 vitamin	 B12	 or	 serum	 iron	 concentration	
(Supplementary	 Table	 6).	 The	 causal	 effects	 estimated	 by	 MR-Egger	 were	 non-
significant	 for	 vitamin	 B12	 (Supplementary	 Table	 5),	 possibly	 as	 a	 result	 of	 the	
reduced	power	of	MR-Egger	 to	detect	 causal	 effects	when	 compared	 to	other	MR	
methodologies(18).		
	
Fatty	acid	profile	and	metabolism	
Fatty	 acid	 (FA)	 metabolism	 involves	 sequential	 enzymatic	 conversions	
(Supplementary	 Figure	 3),	 and	 SNPs	 influencing	 the	 metabolism	 of	 one	 FA	 are	
therefore	 often	 associated	 with	 circulating	 concentrations	 of	 multiple	 FAs(20).	
Additionally,	many	genes	 involved	 in	FA	desaturation	and	elongation	 form	parts	of	
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numerous	FA	pathways,	and	hence	 influence	circulating	concentrations	of	multiple	
classes	of	FA	(Supplementary	Figure	3).	To	limit	bias	introduced	by	such	vertical	and	
horizontal	pleiotropy,	we	restricted	our	analysis	to	classes	of	FAs	(such	as	omega-6	
polyunsaturated	 FAs	 [PUFAs]	 and	 monounsaturated	 FAs	 [MUFAs]),	 rather	 than	
individual	 fatty	acids,	 and	excluded	SNPs	known	 to	be	associated	with	multiple	FA	
classes	 (Supplementary	 Table	 7).	 In	 this	 restricted	 analysis,	 no	 association	 were	
observed	for	omega-6	PUFA	or	MUFA	concentrations,	or	for	blood	levels	of	the	fatty	
acid	transport	molecule	carnitine	(Figure	2).	After	removal	of	potentially	pleiotropic	
SNPs,	only	a	 single	SNP	was	 suitable	 for	use	as	an	 instrumental	variable	 for	MUFA	
concentration,	prohibiting	sensitivity	analysis	using	WME	and	MBE	approaches.		
	
Cardiometabolic	and	inflammatory	factors	
Using	information	on	all	genetic	variants	associated	with	cardiometabolic	factors,	we	
observed	that	measures	of	obesity	and	hyperlipidaemia	were	suggestively	associated	
with	 CRC	 (Figure	 2).	 Specifically,	 suggestive	 associations	 were	 seen	 between	
genetically	predicted	basal	metabolic	rate	(ORSD=1.10,	95%	CI=1.03-1.18,	P=0.0079),	
body	fat	percentage	(ORSD=1.14,	95%	CI=1.03-1.25,	P=0.0086),	BMI	(ORSD=1.09,	95%	
CI=1.01-1.17,	 P=0.023)	 and	 waist	 circumference	 (ORSD=1.13,	 95%	 CI=1.02-1.26,	
P=0.018),	 and	 higher	 odds	 of	 CRC.	 No	 association	 between	 birth	 weight	 or	
adiponectin	 levels	 and	 CRC	 risk	 was	 seen	 (Figure	 2).	 Causal	 estimates	 for	 basal	
metabolic	rate,	BMI	and	waist	circumference	were	broadly	concordant	in	sensitivity	
analyses	using	 the	WME	and	MBE	methods	 (Supplementary	 Table	 5).	 	Conversely,	
the	effect	estimate	for	body	fat	percentage	from	the	MBE	approach	(ORSD=0.98,	95%	
CI=0.72-1.33,	 P=0.90)	 differed	 in	 direction	 to	 the	 estimates	 from	 other	 MR	
implementations	(Supplementary	Table	5),	suggesting	that	some	of	the	instruments	
used	 to	assess	 the	causal	effects	of	body	 fat	percentage	may	be	 invalid.	MR-Egger	
regression	did	not	identify	evidence	of	horizontal	pleiotropy	for	body	fat	percentage	
or	any	other	obesity-related	trait	(Supplementary	Table	6).	
	
Genetically	 predicted	 low-density	 lipoprotein	 (LDL)	 cholesterol	 (ORSD=1.14,	 95%	
CI=1.04-1.25,	 P=0.0056)	 and	 total	 cholesterol	 (ORSD=1.09,	 95%	 CI=1.01-1.18,	
P=0.025)	 showed	 suggestive	 associations	 with	 higher	 odds	 of	 CRC.	 No	 association	
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between	 high-density	 lipoprotein	 (HDL)	 cholesterol	 or	 total	 triglyceride	 levels	 was	
seen	 (Figure	 2).	 Similarly,	 genetically	 predicted	 metrics	 of	 glycaemia	 -	 fasting	
glucose,	fasting	proinsulin,	and	HbA1c	-	were	not	associated	with	CRC	risk	(Figure	2).		
	
Based	on	a	single	SNP,	a	suggestive	association	was	observed	between	plasma	levels	
of	 interleukin	 6	 (IL-6)	 receptor	 subunit	 alpha	 and	 lower	 CRC	 risk	 (ORSD=0.98,	 95%	
CI=0.98-1.00,	 P=0.035).	 Associations	 between	 circulating	 C-reactive	 protein	 and	
serum	immunoglobulin	E	and	CRC	risk	were	not	however	demonstrated	(Figure	2).	
	
Sex	hormones	and	reproduction	
It	has	been	hypothesised	that	sex-specific	differences	in	CRC	incidence	may	be	partly	
attributable	 to	 differential	 sex	 hormone	 exposure(21).	 However,	 we	 observed	 no	
association	 between	 age	 at	 menarche,	 a	 surrogate	 for	 endogenous	 estrogen	
exposure,	and	CRC	risk	 (ORSD=0.99,	95%	CI=0.84-1.18,	P=0.92)	using	CRC	data	from	
females	 only.	 Similarly,	we	did	 not	 observe	 associations	 between	plasma	 estradiol	
and	 progesterone	 and	 CRC	 risk	 in	 sex-specific	 analyses	 (Figure	 2).	 The	 genetic	
variants	used	as	instruments	for	these	traits	explain	only	a	small	proportion	of	their	
variance	(Table	1)	and	we	are	therefore	unable	to	exclude	a	small	to	moderate	effect	
of	 sex	 hormone	 exposure	 on	 CRC	 risk.	 MR-Egger	 regression	 analysis	 of	 genetic	
instruments	 for	 age	 at	 menopause	 provided	 evidence	 of	 horizontal	 pleiotropy	
(P=0.01;	Supplementary	Table	6)	and	we	therefore	did	not	consider	this	trait	in	our	
MR	analysis.	
	
Developmental	and	growth	factors	
Whilst	 height	 is	 not	 modifiable	 once	 stabilised	 in	 adulthood,	 it	 is	 influenced	 by	
developmental	factors	and	growth	processes,	which	may	themselves	be	modifiable.	
In	 concordance	with	 evidence	 reviewed	 by	 the	WCRF	 and	AICR(3),	we	 observed	 a	
suggestive	 association	 between	 greater	 genetically	 predicted	 adult	 height	 and	
increased	 odds	 of	 CRC	 (ORSD=1.04,	 95%	CI=1.00-1.08,	P=0.032),	 further	 supporting	
the	 notion	 that	 factors	 during	 childhood	may	 influence	 CRC	 risk.	We	 observed	 no	
association	between	plasma	insulin-like	growth	factor	1	(IGF-1)	and	CRC	risk	(Figure	
2),	 although	 this	 analysis	 was	 conducted	 using	 a	 single	 genetic	 variant	 explaining	
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only	a	small	proportion	of	IGF-1	variance,	and	therefore	had	limited	power	to	detect	
an	effect	(Table	1).	
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DISCUSSION	
	
With	genetic	variants	as	proxies	for	the	putative	risk	factors,	this	MR	study	provides	
suggestive	evidence	for	associations	between	higher	body	fat	percentage,	BMI,	waist	
circumference	 and	 basal	 metabolic	 rate	 and	 increased	 CRC	 risk.	 We	 also	 found	
suggestive	 evidence	 for	 associations	 between	 genetically	 predicted	 LDL	 and	 total	
cholesterol	 and	 risk	 of	 CRC,	 but	 no	 evidence	 of	 associations	 with	 HDL	 or	 total	
triglyceride	 levels.	 The	 suggestive	 association	 between	 genetically	 determined	
higher	serum	vitamin	B12	levels	and	increased	CRC	risk	is	intriguing.	There	was	also	
suggestive	evidence	for	possible	associations	of	genetically	predicted	serum	iron	and	
selenium	concentrations.	
	
Strengths	of	this	study	include	examination	of	multiple	factors	in	relation	to	CRC	risk,	
by	exploiting	data	from	large	GWAS	of	risk	factors	and	CRC.	Many	of	the	putative	risk	
factors	 considered	 in	 this	 study	 have	 not	 previously	 been	 assessed	 using	 MR	
frameworks	 (Supplementary	 Table	 8).	 Of	 those	 factors	 for	 which	 suggestive	
associations	were	 seen	 (Figure	 2),	body	 fat	percentage,	waist	 circumference,	basal	
metabolic	rate,	iron	status,	and	blood	selenium,	serum	vitamin	B12	and	plasma	IL-6	
subunit	alpha	concentrations	have	not	previously	been	considered	in	MR	analyses	of	
CRC	 risk	 (Supplementary	 Table	 8).	 For	 those	CRC	 risk	 factors	 that	 have	previously	
been	 considered	 in	 MR	 analyses(22)	 the	 number	 of	 CRC	 cases	 and	 controls	 we	
consider	here	affords	us	greater	power	to	detect	causal	relationships	and	allows	us	
to	 more	 accurately	 estimate	 effect	 magnitudes.	 For	 example,	 while	 Rodriguez-
Broadbent	et	al.(23)	reported	a	non-significant	association	between	LDL	cholesterol	
and	 risk	 of	 CRC	 (ORSD=1.05,	 95%	 CI=0.92-1.18,	 P=0.49),	 herein	 a	 suggestive	
relationship	was	identified	(ORSD=1.14,	95%	CI=1.04-1.25,	P=0.0056),	possibly	due	to	
increased	power	of	 the	present	 analysis.	By	 comparing	 the	 results	of	 this	 study	 to	
those	 of	 previous	MR	 analyses	 of	 CRC	 risk	we	 are	 also	 able	 to	 identify	 previously	
reported	 causal	 relationships	 that	 may	 represent	 false	 positives,	 such	 as	 an	
association	between	genetically	predicted	C-reactive	protein	concentrations	and	CRC	
risk(24)	(Figure	2;	Supplementary	Table	8).		
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Although	 F-statistics	were	high	 (>10)	 for	 all	 considered	 traits	 (Table	 1),	we	 cannot	
exclude	 the	possibility	 that	 some	of	our	 findings	may	have	been	affected	by	weak	
instrument	bias.	For	19	of	the	traits	for	which	we	identified	no	association	with	CRC	
risk,	our	study	had	<80%	power	to	identify	ORSD<0.91	or	>1.10	(Table	1),	and	we	are	
therefore	unable	 to	exclude	 the	possibility	 that	 these	 traits	have	a	 small	 effect	on	
CRC	risk.		
	
As	with	all	MR	studies,	excluding	pleiotropy	or	an	alternative	direct	causal	pathway	
as	the	basis	of	association	is	a	challenge.	High	I2	statistics	for	many	traits	indicate	the	
presence	 of	 such	 pleiotropy	 in	 this	 analysis	 (Figure	 2).	 To	 address	 this	 issue	 we	
implemented	the	WME	and	MBE	methods,	which	can	provide	unbiased	causal	effect	
estimates	even	when	many	genetic	variants	used	represent	 invalid	 instruments(16,	
17).	For	the	majority	of	traits	with	either	a	significant	or	suggestive	association	with	
CRC	risk,	the	effects	estimated	were	similar	using	MLE-RE,	WME	and	MBE	methods	
(Supplementary	Table	5),	supporting	causal	relationships	with	CRC.	It	is	important	to	
note	that	there	exists	overlap	between	the	CRC	cases	and	controls	considered	in	this	
study,	and	those	considered	in	some	previous	MR	analyses(22),	and	that	results	from	
this	study	therefore	cannot	be	considered	independent	replication.		
	
Our	 study	 provides	 no	 evidence	 for	 an	 association	 between	 genetically	 predicted	
fasting	glucose	and	proinsulin	and	risk	of	CRC,	suggesting	that	metabolic	syndrome	
may	not	influence	CRC	risk	through	these	factors.	However,	due	to	the	limited	power	
of	 this	 analysis,	we	 cannot	preclude	 these	 factors	having	 small	 effects	on	CRC	 risk	
(Table	1).		
	
Our	 estimate	 that	 an	 SD	 increment	 in	 adult	 height	 increases	 CRC	 risk	 by	 4%	 is	
concordant	 with	 many	 observational	 studies(3),	 with	 greater	 exposure	 to	 growth	
hormones	and	insulin-like	growth	factors	during	childhood	being	posited	as	potential	
mechanisms	 for	 this	 association(26).	Whilst	we	observed	no	 significant	 association	
between	 plasma	 IGF-1	 and	 CRC	 risk	 (Figure	 2),	 the	 limited	 power	 of	 this	 analysis	
means	that	we	are	unable	to	exclude	small	to	moderate	effect	sizes	(Table	1).	Taller	
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adults	tend	to	have	larger	colons,	and	so	greater	at-risk	cell	populations	might	also	
explain	the	apparent	causal	inference.	
	
Of	 the	 nutritional	 factors	 analysed,	 a	 relationship	 between	 genetically	 predicted	
vitamin	B12	 levels	and	CRC	 risk	was	 shown	 (Supplementary	 Table	 5).	Our	 findings	
are	 concordant	 with	 a	 randomized	 trial	 that	 found	 vitamin	 B12	 supplementation	
increases	CRC	risk(29).	Although	less	convincing,	we	also	found	suggestive	evidence	
to	 support	 high	 selenium	 levels	 having	 a	 beneficial	 effect	 and	 greater	 iron	 status	
being	detrimental	(Supplementary	Table	5).		
	
Inevitably,	 further	 research	 is	 required	 to	 decipher	 the	 biological	 pathways	
underpinning	 associations.	 However,	 irrespective	 of	 the	 exact	 functional	 basis	 of	
associations	using	a	genetic	approach,	our	analysis	highlights	 important	 targets	 for	
primary	prevention	of	CRC	in	the	population.	Firstly,	between	obesity	and	CRC	risk,	
the	 strong	 corroboration	 for	 obesity	 being	 a	 major	 risk	 factor	 for	 CRC	 supports	
reducing	 the	 population	 incidence	 of	 obesity	 a	 priority.	 Secondly,	 our	 findings	 are	
consistent	 with	 hypercholesterolemia	 being	 causally	 linked	 to	 risk	 and	 therefore	
support	 the	 hypothesis	 that	 the	 increasing	 use	 of	 statins	 in	 the	 population	 for	
prevention	 of	 cardiovascular	 disease	 will	 have	 the	 added	 bonus	 of	 reducing	 CRC	
burden.	The	limited	power	of	this	study	to	refine	robustly	the	relationship	between	
some	putative	risk	factors	provides	motivation	for	larger	MR	studies	to	demonstrate	
relationships	 for	 the	 spectrum	 of	 colorectal	 neoplasia.	 Such	 work	 may	 shed	
additional	light	on	other	potentially	modifiable	factors	to	reduce	the	overall	burden	
of	CRC.		
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FIGURES	
	
Figure	1:	Principles	of	Mendelian	randomisation	and	the	assumptions	that	need	to	
be	 satisfied	 to	 derive	 unbiased	 causal	 effect	 estimates.	 Dashed	 lines	 represent	
direct	 causal	 and	 potential	 pleiotropic	 effects	 that	 would	 violate	 Mendelian	
randomisation	assumptions.	A1:	Genetic	variants	used	as	instrumental	variables	are	
associated	with	the	risk	 factor;	A2:	Genetic	variants	 influence	the	risk	of	colorectal	
cancer	only	through	the	risk	factor;	A3:	Genetic	variants	are	not	associated	with	any	
measured	or	unmeasured	confounders.	SNP:	single	nucleotide	polymorphism.		
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Figure	 2:	 Odds	 ratios	 for	 associations	 between	 genetically	 predicted	 risk	 factors	
and	 colorectal	 cancer.	 Results	 reported	 as	 odds	 ratios	 (ORSD)	 and	 95%	 confidence	
intervals	(CIs)	per	genetically	predicted	standard	deviation	(SD)	unit	 increase	 in	the	
risk	 factor.	 A	maximum	 likelihood	 estimate	 random-effects	 (MLE-RE)	 method	 was	
used	 to	 summarize	 Wald	 ratio	 estimates	 from	 individual	 single	 nucleotide	
polymorphisms	(SNPs).	IL-6	sRa:	interleukin	6	receptor	subunit	alpha;	IGF:	insulin-like	
growth	 factor.	 *	 P	 <	 0.05;	 	 ‡	 ORSD	 from	 restricted	 analysis,	 which	 excludes	 SNPs	
known	to	be	associated	with	other	classes	of	fatty	acid.	†	ORSD	computed	using	CRC	
data	from	female	cases	and	controls.		 	
Diet and lifestyle
Fatty acid profile
and metabolism
Inflammatory factors
Lipids and
lipid transport
Obesity
Trait
Height
Plasma IGF−I
Alcohol consumption
Blood methionine
Blood selenium
Blood zinc
Circulating 25−hydroxyvitamin D
Circulating carotenoids
Coffee consumption
Iron status
Serum calcium
Serum vitamin A (retinol)
Serum vitamin B12
Serum vitamin B6
Serum vitamin E
Blood carnitine
Mono−unsaturated fatty acids‡
Omega−6 polyunsaturated fatty acids‡ 
Circulating C−reactive protein
Plasma IL−6 sRa
Serum IgE
Circulating fetuin−A
HDL cholesterol
LDL cholesterol
Total cholesterol
Total triglycerides
Basal metabolic rate
Birth weight
Body fat percentage
Body mass index
Circulating adiponectin
Fasting glucose
Fasting proinsulin
HbA1C levels
Waist circumference
Waist−to−hip ratio
No. SNPs
2487
1
3
1
1
2
5
1
4
3
8
2
9
1
3
18
1
6
14
1
3
1
58
44
28
34
693
93
370
964
10
23
8
11
319
35
0.8 1 1.2 1.4 1.6 1.8
ORSD
ORSD (95% CI)
1.04 (1.00−1.08)
0.88 (0.76−1.01)
1.60 (0.85−3.04)
0.92 (0.70−1.19)
0.85 (0.75−0.96)
0.94 (0.86−1.03)
0.99 (0.90−1.09)
1.04 (0.94−1.15)
1.17 (0.88−1.55)
1.17 (1.00−1.36)
0.93 (0.83−1.05)
1.07 (0.78−1.47)
1.21 (1.04−1.42)
1.04 (0.90−1.20)
0.94 (0.76−1.17)
0.99 (0.92−1.06)
1.07 (0.78−1.46)
1.15 (0.98−1.36)
0.95 (0.83−1.10)
0.98 (0.96−1.00)
0.92 (0.82−1.03)
0.98 (0.94−1.02)
1.03 (0.92−1.14)
1.14 (1.04−1.25)
1.09 (1.01−1.18)
0.93 (0.84−1.04)
1.10 (1.03−1.18)
1.10 (0.92−1.31)
1.14 (1.03−1.25)
1.09 (1.01−1.17)
0.93 (0.81−1.07)
1.04 (0.92−1.18)
0.97 (0.90−1.03)
1.02 (0.85−1.22)
1.13 (1.02−1.26)
1.07 (0.91−1.27)
P-value
0.032
0.064
0.146
0.505
0.008
0.179
0.895
0.451
0.269
0.049
0.264
0.663
0.016
0.592
0.600
0.682
0.672
0.095
0.527
0.035
0.159
0.370
0.620
0.006
0.025
0.192
0.008
0.308
0.009
0.023
0.309
0.519
0.310
0.866
0.018
0.412
*
*
*
*
*
*
*
*
*
*
*
Sex hormones
and reproduction
Age at menarche†
Plasma estradiol†
Plasma progesterone†
151
1
2
0.99 (0.84−1.18)
1.27 (0.53−3.02)
0.90 (0.76−1.07)
0.924
0.587
0.239
I2
39.4
-
60.0
-
-
0.0
0.0
-
20.9
0.0
18.8
59.4
71.9
-
0.0
53.4
-
53.1
56.5
-
0.0
-
53.5
53.4
32.2
51.5
46.7
57.9
37.1
31.1
0.0
48.8
0.0
51.7
38.0
41.5
20.4
-
0.0
Developmental and
growth factors
		 22	
REFERENCES	
	
1.	 Bray	F,	Ferlay	J,	Soerjomataram	I,	Siegel	RL,	Torre	LA,	Jemal	A.	Global	cancer	
statistics	 2018:	GLOBOCAN	 estimates	 of	 incidence	 and	mortality	worldwide	 for	 36	
cancers	in	185	countries.	CA	Cancer	J	Clin.	2018;68(6):394-424.	
2.	 Flood	DM,	Weiss	NS,	Cook	LS,	Emerson	JC,	Schwartz	SM,	Potter	JD.	Colorectal	
cancer	 incidence	 in	 Asian	 migrants	 to	 the	 United	 States	 and	 their	 descendants.	
Cancer	Causes	Control.	2000;11(5):403-11.	
3.	 WCRF,	AICR.	Diet,	nutrition,	physical	activity	and	colorectal	cancer.	2018.	
4.	 Fewell	Z,	Davey	Smith	G,	Sterne	JA.	The	impact	of	residual	and	unmeasured	
confounding	 in	 epidemiologic	 studies:	 a	 simulation	 study.	 Am	 J	 Epidemiol.	
2007;166(6):646-55.	
5.	 Cole	 BF,	 Logan	 RF,	 Halabi	 S,	 Benamouzig	 R,	 Sandler	 RS,	 Grainge	MJ,	 et	 al.	
Aspirin	 for	 the	 chemoprevention	 of	 colorectal	 adenomas:	 meta-analysis	 of	 the	
randomized	trials.	J	Natl	Cancer	Inst.	2009;101(4):256-66.	
6.	 Baron	 JA,	 Beach	M,	Mandel	 JS,	 van	 Stolk	 RU,	 Haile	 RW,	 Sandler	 RS,	 et	 al.	
Calcium	 supplements	 for	 the	 prevention	 of	 colorectal	 adenomas.	 Calcium	 Polyp	
Prevention	Study	Group.	N	Engl	J	Med.	1999;340(2):101-7.	
7.	 Tarasuk	 VS,	 Brooker	 AS.	 Interpreting	 epidemiologic	 studies	 of	 diet-disease	
relationships.	J	Nutr.	1997;127(9):1847-52.	
8.	 Davey	 Smith	 G,	 Hemani	 G.	 Mendelian	 randomization:	 genetic	 anchors	 for	
causal	inference	in	epidemiological	studies.	Hum	Mol	Genet.	2014;23(R1):R89-98.	
9.	 Law	PJ,	Timofeeva	M,	Fernandez-Rozadilla	C,	Broderick	P,	Studd	J,	Fernandez-
Tajes	 J,	 et	 al.	 Association	 analyses	 identify	 31	 new	 risk	 loci	 for	 colorectal	 cancer	
susceptibility.	Nat	Commun.	2019;10(1):2154.	
10.	 Shim	 H,	 Chasman	 DI,	 Smith	 JD,	Mora	 S,	 Ridker	 PM,	 Nickerson	 DA,	 et	 al.	 A	
multivariate	 genome-wide	 association	 analysis	 of	 10	 LDL	 subfractions,	 and	 their	
response	to	statin	treatment,	in	1868	Caucasians.	PLoS	One.	2015;10(4):e0120758.	
11.	 Disney-Hogg	 L,	 Cornish	 AJ,	 Sud	 A,	 Law	 PJ,	 Kinnersley	 B,	 Jacobs	 DI,	 et	 al.	
Impact	 of	 atopy	 on	 risk	 of	 glioma:	 a	 Mendelian	 randomisation	 study.	 BMC	 Med.	
2018;16(1):42.	
		 23	
12.	 Hemani	G,	 Zheng	 J,	 Elsworth	B,	Wade	KH,	Haberland	V,	 Baird	D,	 et	 al.	 The	
MR-Base	platform	supports	systematic	causal	inference	across	the	human	phenome.	
Elife.	2018;7.	
13.	 Burgess	S,	Davies	NM,	Thompson	SG.	Bias	due	to	participant	overlap	in	two-
sample	Mendelian	randomization.	Genet	Epidemiol.	2016;40(7):597-608.	
14.	 Lawlor	 DA,	 Harbord	 RM,	 Sterne	 JA,	 Timpson	N,	 Davey	 Smith	 G.	Mendelian	
randomization:	 using	 genes	 as	 instruments	 for	 making	 causal	 inferences	 in	
epidemiology.	Stat	Med.	2008;27(8):1133-63.	
15.	 Yavorska	 OO,	 Burgess	 S.	 MendelianRandomization:	 an	 R	 package	 for	
performing	 Mendelian	 randomization	 analyses	 using	 summarized	 data.	 Int	 J	
Epidemiol.	2017;46(6):1734-9.	
16.	 Bowden	 J,	 Davey	 Smith	G,	 Haycock	 PC,	 Burgess	 S.	 Consistent	 Estimation	 in	
Mendelian	Randomization	with	Some	Invalid	Instruments	Using	a	Weighted	Median	
Estimator.	Genet	Epidemiol.	2016;40(4):304-14.	
17.	 Hartwig	 FP,	 Davey	 Smith	 G,	 Bowden	 J.	 Robust	 inference	 in	 summary	 data	
Mendelian	randomization	via	the	zero	modal	pleiotropy	assumption.	Int	J	Epidemiol.	
2017;46(6):1985-98.	
18.	 Bowden	 J,	Davey	Smith	G,	Burgess	S.	Mendelian	 randomization	with	 invalid	
instruments:	 effect	 estimation	 and	 bias	 detection	 through	 Egger	 regression.	 Int	 J	
Epidemiol.	2015;44(2):512-25.	
19.	 Brion	 MJ,	 Shakhbazov	 K,	 Visscher	 PM.	 Calculating	 statistical	 power	 in	
Mendelian	randomization	studies.	Int	J	Epidemiol.	2013;42(5):1497-501.	
20.	 Wu	 JH,	 Lemaitre	 RN,	 Manichaikul	 A,	 Guan	 W,	 Tanaka	 T,	 Foy	 M,	 et	 al.	
Genome-wide	association	study	identifies	novel	 loci	associated	with	concentrations	
of	four	plasma	phospholipid	fatty	acids	 in	the	de	novo	lipogenesis	pathway:	results	
from	the	Cohorts	for	Heart	and	Aging	Research	in	Genomic	Epidemiology	(CHARGE)	
consortium.	Circ	Cardiovasc	Genet.	2013;6(2):171-83.	
21.	 Koo	 JH,	 Leong	 RW.	 Sex	 differences	 in	 epidemiological,	 clinical	 and	
pathological	 characteristics	 of	 colorectal	 cancer.	 J	 Gastroenterol	 Hepatol.	
2010;25(1):33-42.	
		 24	
22.	 Cornish	 AJ,	 Tomlinson	 IPM,	 Houlston	 RS.	 Mendelian	 randomisation:	 A	
powerful	 and	 inexpensive	 method	 for	 identifying	 and	 excluding	 non-genetic	 risk	
factors	for	colorectal	cancer.	Mol	Aspects	Med.	2019.	
23.	 Rodriguez-Broadbent	H,	 Law	PJ,	 Sud	A,	 Palin	 K,	 Tuupanen	 S,	Gylfe	 A,	 et	 al.	
Mendelian	 randomisation	 implicates	 hyperlipidaemia	 as	 a	 risk	 factor	 for	 colorectal	
cancer.	Int	J	Cancer.	2017;140(12):2701-8.	
24.	 Nimptsch	 K,	 Aleksandrova	 K,	 Boeing	 H,	 Janke	 J,	 Lee	 YA,	 Jenab	 M,	 et	 al.	
Association	of	CRP	genetic	variants	with	blood	concentrations	of	C-reactive	protein	
and	colorectal	cancer	risk.	Int	J	Cancer.	2015;136(5):1181-92.	
25.	 Burgess	 S,	Bowden	 J,	 Fall	 T,	 Ingelsson	E,	 Thompson	SG.	 Sensitivity	Analyses	
for	Robust	Causal	 Inference	from	Mendelian	Randomization	Analyses	with	Multiple	
Genetic	Variants.	Epidemiology.	2017;28(1):30-42.	
26.	 Gunnell	 D,	Okasha	M,	 Smith	GD,	Oliver	 SE,	 Sandhu	 J,	 Holly	 JM.	Height,	 leg	
length,	and	cancer	risk:	a	systematic	review.	Epidemiol	Rev.	2001;23(2):313-42.	
27.	 Bartsch	H,	Nair	J,	Owen	RW.	Dietary	polyunsaturated	fatty	acids	and	cancers	
of	 the	 breast	 and	 colorectum:	 emerging	 evidence	 for	 their	 role	 as	 risk	 modifiers.	
Carcinogenesis.	1999;20(12):2209-18.	
28.	 Wang	D,	DuBois	RN.	The	role	of	anti-inflammatory	drugs	in	colorectal	cancer.	
Annu	Rev	Med.	2013;64:131-44.	
29.	 Oliai	Araghi	S,	Kiefte-de	Jong	JC,	van	Dijk	SC,	Swart	KMA,	van	Laarhoven	HW,	
van	Schoor	NM,	et	al.	Folic	Acid	and	Vitamin	B12	Supplementation	and	the	Risk	of	
Cancer:	 Long-term	Follow-up	of	 the	B	Vitamins	 for	 the	Prevention	of	Osteoporotic	
Fractures	(B-PROOF)	Trial.	Cancer	Epidemiol	Biomarkers	Prev.	2019;28(2):275-82.	
	
	
		 1	
Risk	factor	class	 Trait	
PubMed	
ID	
Number	
of	SNPs	
used	in	
MR	
analysis	
PVE	
by	
SNPs	
Power	to	
identify	
ORSD	of	
0.91	or	
1.10	
Power	to	
identify	
ORSD	of	
0.75	or	
1.33	 F-statistic	
Developmental	and	growth	
factors	 Height	 30124842	 2487	 0.380	 1.000	 1.000	 171.41	
Developmental	and	growth	
factors	 Plasma	IGF-I	 29875488	 1	 0.014	 0.314	 0.995	 48.51	
Diet	and	lifestyle	 Alcohol	consumption	 28937693	 3	 0.002	 0.082	 0.364	 66.73	
Diet	and	lifestyle	 Blood	methionine	 24816252	 1	 0.004	 0.124	 0.676	 30.57	
Diet	and	lifestyle	 Blood	selenium	 23720494	 1	 0.020	 0.417	 1.000	 114.36	
Diet	and	lifestyle	 Blood	zinc	 23720494	 2	 0.046	 0.746	 1.000	 62.58	
Diet	and	lifestyle	 Circulating	25-hydroxyvitamin	D	 29343764	 5	 0.026	 0.512	 1.000	 431.37	
Diet	and	lifestyle	 Circulating	carotenoids	 19185284	 1	 0.028	 0.531	 1.000	 106.36	
Diet	and	lifestyle	 Coffee	consumption	 25288136	 4	 0.005	 0.147	 0.788	 124.16	
Diet	and	lifestyle	 Iron	status	 25352340	 3	 0.012	 0.260	 0.981	 190.40	
Diet	and	lifestyle	 Serum	calcium	 24068962	 8	 0.026	 0.503	 1.000	 202.32	
Diet	and	lifestyle	 Serum	vitamin	A	(retinol)	 21878437	 2	 0.007	 0.175	 0.879	 34.69	
Diet	and	lifestyle	 Serum	vitamin	B12	 23754956	 9	 0.047	 0.760	 1.000	 252.08	
Diet	and	lifestyle	 Serum	vitamin	B6	 19303062	 1	 0.014	 0.307	 0.994	 26.67	
Diet	and	lifestyle	 Serum	vitamin	E	 21729881	 3	 0.007	 0.167	 0.857	 10.92	
Fatty	acid	profile	and	
metabolism	 Blood	carnitine	 24816252	 18	 0.139	 0.995	 1.000	 65.81	
Fatty	acid	profile	and	
metabolism	 Mono-unsaturated	fatty	acids*	 27005778	 1	 0.003	 0.097	 0.493	 36.29	
Fatty	acid	profile	and	
metabolism	
Omega-6	polyunsaturated	fatty	
acids*	 27005778	 6	 0.024	 0.477	 1.000	 55.68	
Inflammatory	factors	 Circulating	C-reactive	protein	 21300955	 14	 0.036	 0.640	 1.000	 220.09	
Inflammatory	factors	
Plasma	IL-6	receptor	subunit	
alpha	 29875488	 1	 0.604	 1.000	 1.000	 5038.85	
Inflammatory	factors	 Serum	immunoglobulin	E	 22075330	 3	 0.016	 0.342	 0.997	 79.70	
Lipids	and	lipid	transport	 Circulating	fetuin-A	 28379451	 1	 0.143	 0.996	 1.000	 1331.92	
Lipids	and	lipid	transport	
High-density	lipoprotein	
cholesterol	 24097068	 58	 0.061	 0.856	 1.000	 105.31	
Lipids	and	lipid	transport	
Low-density	lipoprotein	
cholesterol	 24097068	 44	 0.079	 0.930	 1.000	 182.74	
Lipids	and	lipid	transport	 Total	cholesterol	 27005778	 28	 0.095	 0.964	 1.000	 80.05	
Lipids	and	lipid	transport	 Total	triglycerides	 24097068	 34	 0.061	 0.857	 1.000	 180.23	
Obesity	 Basal	metabolic	rate	 30305743	 693	 0.122	 0.990	 1.000	 66.11	
Obesity	 Birth	weight	 30305743	 93	 0.025	 0.487	 1.000	 52.72	
Obesity	 Body	fat	percentage	 30305743	 370	 0.053	 0.806	 1.000	 50.28	
Obesity	 Body	mass	index	 30124842	 964	 0.079	 0.929	 1.000	 60.69	
Obesity	 Circulating	adiponectin	 22479202	 10	 0.018	 0.372	 0.999	 65.12	
Obesity	 Fasting	glucose	 22581228	 23	 0.036	 0.639	 1.000	 93.73	
Obesity	 Fasting	proinsulin	 20081858	 8	 0.061	 0.858	 1.000	 87.33	
Obesity	 HbA1C	levels	 20858683	 11	 0.018	 0.381	 0.999	 78.72	
Obesity	 Waist	circumference	 30305743	 319	 0.047	 0.754	 1.000	 51.68	
Obesity	 Waist-to-hip	ratio	 25673412	 35	 0.018	 0.369	 0.999	 57.66	
Sex	hormones	and	
reproduction	 Age	at	menarche**	 30305743	 151	 0.048	 0.303	 0.993	 58.11	
		 2	
Sex	hormones	and	
reproduction	 Plasma	estradiol**	 26014426	 1	 0.011	 0.105	 0.553	 31.47	
Sex	hormones	and	
reproduction	 Plasma	progesterone**	 26014426	 2	 0.035	 0.235	 0.965	 52.44	
	
Table	 1:	 Modifiable	 risk	 factors	 considered.	 Given	 are	 the	 number	 of	 trait-associated	 single	
nucleotide	 polymorphisms	 (SNPs)	 employed	 as	 instrumental	 variables	 in	 the	 Mendelian	
randomisation	 (MR)	 framework,	 the	 PubMed	 ID	 of	 the	manuscript	 from	which	 these	 SNPs	were	
obtained,	the	proportion	of	trait	variance	explained	by	these	SNPs	(PVE)	and	the	analysis	power	to	
detect	 causal	 effects	 at	 given	 odds	 ratios.	 Odds	 ratios	 of	 colorectal	 cancer	 risk	 are	 given	 per	
genetically	predicted	standard	deviation	unit	increase	in	risk	factor	(ORSD).	The	F-statistic	is	used	as	
a	measure	of	potential	weak	instrument	bias,	with	a	low	statistic	(F<10)	indicative	of	possible	bias.	
*	 Results	 from	 restricted	 analysis,	which	 excludes	 SNPs	 known	 to	 be	 associated	with	 other	 fatty	
acid	classes.	**	Causal	effects	estimated	using	colorectal	 cancer	 summary	statistics	 from	 females	
only.	
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SUPPLEMENTARY	METHODS	
	
Identification	of	potentially	modifiable	risk	factors	
To	identify	epidemiological	meta-analyses	of	colorectal	cancer	(CRC)	risk	factors	we	
searched	PubMed	with	the	terms:	‘((((colorectal	cancer)	OR	colon	cancer)	OR	rectal	
cancer)	AND	risk	factor)	AND	meta	analysis’,	 restricting	our	search	to	reviews	from	
the	 previous	 five	 years	 (search	 conducted	 30	 November	 2018).	 Mendelian	
randomisation	(MR)	analyses	of	CRC	risk	factors	were	identified	by	further	searching	
PubMed	 with	 the	 terms:	 ‘(((colorectal	 cancer)	 OR	colon	 cancer)	 OR	rectal	 cancer)	
AND	 ((Mendelian	randomization)	 OR	Mendelian	randomisation)’	 (search	 conducted	
1	March	2019).	
	
Genetic	instruments	for	putative	risk	factors	
We	 obtained	 instruments	 for	 two	 developmental	 and	 growth	 factor1,2,	 three	 sex	
hormones	 and	 reproduction3,4,	 three	 fatty	 acid	 (FA)5,6,	 three	 inflammatory2,7,8,	 five	
lipid6,9,10,	 ten	 obesity1,3,11-16,	 and	 13	 other	 diet	 and	 lifestyle-related	 traits5,17-27	
(Supplementary	Table	2).		
	
The	genetic	architectures	of	smoking	initiation	and	number	of	cigarettes	smoked	per	
day	 differ28,	 and	 these	 traits	 therefore	 need	 to	 be	 considered	 separately	 in	 MR	
analyses.	 Smoking	 initiation	 is	 a	 binary	 trait	 and	 was	 therefore	 not	 included,	 as	
analysis	of	binary	exposures	with	binary	outcomes	using	two-sample	MR	frameworks	
can	result	 in	 inaccurate	causal	estimates29.	Smoking	status	data	were	not	available	
for	 all	 CRC	 genome-wide	 association	 study	 (GWAS)	 individuals,	 and	 we	 were	
therefore	 also	 unable	 to	 include	 number	 of	 cigarettes	 smoked	 per	 day	 in	 this	
analysis.		
	
For	 each	 SNP	 used	 as	 a	 genetic	 instrument,	 we	 obtained	 the	 per-allele	 effect	
estimate	on	the	putative	risk	factor,	the	standard	error	(SE)	of	this	estimate,	and	the	
effect	and	reference	alleles	(Supplementary	Table	2)	from	the	corresponding	GWAS	
Cornish	et	al.	
	 2	
(Table	1).	We	standardized	effect	estimates	to	represent	the	effect	of	each	SNP	on	
the	 trait	 in	 units	 of	 standard	 deviation	 (SD).	 Association	 strengths	 of	 genetic	
instruments	for	each	putative	risk	factor	were	quantified	by	the	F-statistic	(Table	1),	
with	F>10	considered	indicative	of	a	strong	instrument30.		
	
A	 central	 assumption	 of	MR	 is	 that	 SNPs	 used	 as	 instrumental	 variables	 (IVs)	 are	
associated	with	the	outcome	only	through	the	exposure,	and	are	not	confounded	by	
pleiotropy31.	 A	 number	 of	 genes,	 including	FADS1,	FADS2	 and	ELOVL2,	 control	 the	
metabolism	 of	multiple	 FAs	 (Supplementary	 Figure	 3),	 and	 SNPs	 at	 these	 loci	 are	
therefore	 associated	 with	 circulating	 concentrations	 of	 more	 than	 one	 FA32,33.	
Assessing	the	effect	of	pleiotropy	on	MR	causal	estimates	using	approaches	such	as	
MR-Egger,	 weighted	 median	 estimator	 (WME)	 and	 mode-based	 estimates	 (MBE),	
requires	multiple	 SNPs	 to	 be	 used	 as	 IVs.	 As	many	 FAs	 have	 only	 been	 associated	
with	a	single	or	small	number	of	SNPs33,	it	is	not	possible	to	use	such	methods,	and	
we	 therefore	 restricted	 our	 analysis	 of	 FAs	 on	 CRC	 risk	 to	 limit	 potential	 bias	
introduced	by	pleiotropic	SNPs.		
	
FA	metabolism	involves	sequential	enzymatic	conversions	(Supplementary	Figure	3),	
and	 SNPs	 influencing	 the	metabolism	 of	 one	 FA	 can	 therefore	 be	 associated	with	
circulating	concentrations	of	multiple	FAs	of	the	same	class	(i.e.	vertical	pleiotropy).	
To	limit	the	effect	of	vertical	pleiotropy,	we	therefore	considered	classes	of	FA	(i.e.	
omega-3	polyunsaturated	fatty	acids	[PUFAs],	omega-6	PUFAs	and	monounsaturated	
fatty	acids	[MUFAs]),	rather	than	individual	FAs,	in	our	primary	analysis.		
	
Many	genes	involved	in	FA	desaturation	and	elongation,	such	as	FADS1	and	ELOVL2,	
form	 parts	 of	 multiple	 FA	 pathways	 (Supplementary	 Figure	 3),	 and	 therefore	
influence	 the	 circulating	 concentrations	 of	 FAs	 from	 more	 than	 one	 class	 (i.e.	
horizontal	 pleiotropy).	 To	 limit	 the	 effects	 of	 horizontal	 pleiotropy,	 we	 therefore	
excluded	SNPs	known	to	be	associated	with	multiple	classes	of	FA	(Supplementary	
Table	 7).	 Such	 potentially	 pleiotropic	 SNPs	 were	 identified	 using	 genome-wide	
significant	 SNPs	 from	 four	 GWAS6,32,34,35.	 SNPs	 were	 excluded	 if	 they	 themselves	
were	associated	with	multiple	FA	classes,	were	in	linkage	disequilibrium	with	a	SNP	
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associated	with	another	FA	class	(r2>0.01),	or	were	within	500kb	of	a	SNP	associated	
with	another	FA	class.	 In	our	primary	analysis	we	consider	only	SNPs	not	known	to	
be	associated	with	another	class	of	FA	(Figure	2,	Supplementary	Table	5).		
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Supplementary	 Figure	 1:	 Study	 design	 flowchart.	 CRC:	 colorectal	 cancer;	 MR:	
Mendelian	randomization;	SNP:	single	nucleotide	polymorphism.	
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Supplementary	 Figure	 2	 (Page	 4/4):	 Funnel	 plots	 of	 causal	 estimates	 (βIV)	 and	
instrument	 strength	 (1/SEIV)	 for	 each	 genetic	 variant	 used	 as	 an	 instrumental	
variable.	 Causal	 estimates	 computed	 as	 the	 log	 of	 the	Wald	 ratio	 per	 genetically	
predicted	 standard	 deviation	 unit	 increase	 in	 the	 risk	 factor.	 Red	 lines	 represent	
causal	effect	estimated	using	a	maximum	likelihood	estimate	random-effects	(MLE-
RE)	 model.	 Dotted	 lines	 represent	 the	 null.	 SNP:	 single	 nucleotide	 polymorphism;	
HDL:	 high-density	 lipoprotein;	 LDL:	 low-density	 lipoprotein.	 *Causal	 effects	
estimated	using	colorectal	cancer	data	from	females	only.				
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Supplementary	Figure	3:	Fatty	acid	pathways.	Shown	are	the	fatty	acids	considered	
in	this	MR	analysis	(coloured)	and	the	genes	encoding	the	enzymes	catalyzing	each	
pathway	step.		
